ARCA biopharma (ABIO) Stock Research, Analysis & News

Quick Analysis on ARCA biopharma (ABIO) Stock as of April 29, 2017

Previous Closing Price $2.70 is above 50 day moving average of $2.49
Previous Closing Price $2.70 is above 200 day moving average of $2.50
The Stock pays no dividend
The closing price $2.70 is more than 511.11% away from its one year target price of $16.50
Good Price to Book Ratio of 1.10
Current Short Ratio 2.02 is great than 1
Earning per Share $-1.81 is negative. ARCA biopharma is lossing money.
EBITDA $-16.29M is negative
Average trading volume is relatively low at 26,562
It is a very small cap stock with market cap of $24.19M
(See more information about ARCA biopharma (ABIO) Stock below)

ARCA biopharma (ABIO) Stock Profile Summary

ARCA biopharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of genetically-targeted therapies for heart failure and other cardiovascular diseases in the United States. The companys lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator for the treatment of chronic heart failure and other indications. Its development pipeline includes rNAPc2, a long-acting recombinant protein anticoagulant with a mechanism of action involving inhibition of tissue factor; and NU172, a short-acting anticoagulant, under collaboration agreement with Archemix Corporation, used during medical or surgical procedures. ARCA biopharma has a collaboration agreement with Laboratory Corporation of America to develop the genetic test for Gencaro. The company is headquartered in Broomfield, Colorado.

ARCA biopharma (ABIO) Stock Key Statistics Research and Analysis as of April 29, 2017

Stock ExchangeNCM
Market Capitalization$24.19M
Trade Volume (Average Trading Volume)18,642 (26,562)
Price/Book1.10
Earning/Share$-1.81
Current Year EPS Estimate$-1.75
Next Year EPS Estimate$-1.19
Previous Closing Price$2.70
50 Day Price Moving Average$2.49
200 Day Price Moving Average$2.50
1 yr Target Price$16.50
PEG Ratio0.00
Short Ratio2.02
EBITDA$-16.29M

ARCA biopharma (ABIO) Stock Competitor Research and Analysis

AstraZeneca PLC (AZN)GlaxoSmithKline plc (GSK)
Amgen Inc. (AMGN)Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)Sanofi-Aventis (SNY)
Novartis AG (NVS)

Latest Market News on ARCA biopharma (ABIO)


Click here to find the latest news on ARCA biopharma (ABIO)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

AstraZeneca PLC (AZN)
GlaxoSmithKline plc (GSK)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
Sanofi-Aventis (SNY)
Novartis AG (NVS)